Azithromycin Dosing for Suspected Pulmonary MAC

Disease Pattern Determines Dosing Frequency

The American Thoracic Society recommends daily oral azithromycin 250 mg combined with ethambutol and rifampin for all cavitary MAC pulmonary disease 2
Daily therapy is mandatory for cavitary disease because intermittent dosing carries high risk of macrolide resistance development and treatment failure 2
Consider adding intravenous amikacin for the initial 2 months when AFB smear-positive sputum, severe radiological findings, or systemic illness are present 2, 3
The American Thoracic Society suggests azithromycin 500 mg three times weekly combined with rifampin and ethambutol for noncavitary disease 1, 4
Intermittent therapy is better tolerated with fewer adverse events leading to discontinuation compared to daily regimens 4

Macrolide monotherapy rapidly induces macrolide resistance, rendering future treatment extremely difficult 2, 4
All patients must receive at least three drugs: a macrolide (azithromycin), ethambutol, and a rifamycin 2, 3
A two-drug regimen (macrolide plus ethambutol alone) should never be used for cavitary disease due to high risk of macrolide resistance emergence 2, 4
Rifampin 10 mg/kg daily (maximum 600 mg) completes the standard regimen, though rifabutin 150-300 mg daily may substitute if drug interactions necessitate 2

Monthly sputum cultures must be obtained throughout treatment to assess microbiologic response 2, 4
Clinical improvement is expected within 3-6 months, with sputum conversion to negative expected within 12 months 2, 4
If sputum cultures remain positive after 6 months of appropriate therapy, investigate medication adherence, drug intolerance, macrolide resistance, and anatomic limitations 2

Obtain baseline ECG to assess QTc interval before initiating azithromycin; contraindicated if QTc >450 ms (men) or >470 ms (women) 5
Perform baseline liver function tests, repeat at 1 month, then every 6 months 5
Monthly vision checks are required for patients on ethambutol, especially with prolonged therapy 2

Patients respond best to MAC treatment the first time they receive it—use the full recommended multidrug regimen initially rather than attempting inadequate therapy 2
Never use intermittent therapy for cavitary disease, previously treated patients, or those with moderate-to-severe disease 4
In cystic fibrosis patients, the CF Foundation explicitly recommends against intermittent (three times weekly) therapy for any MAC pulmonary disease 3, 6